The Changing Landscape for HER2+ Advanced Metastatic Breast Cancer
An international perspective pertaining to treatment advances in HER2-positive metastatic breast cancer and how to best apply data from ESMO 2021 into daily practice.
EP. 1: Global Trends in HER2+ MBC
Carmen Criscitiello, MD, PhD
Breast oncologists from across the globe react to incidence rates of HER2-positive metastatic breast cancer as they relate to rates of progression to brain metastases and treatment advances.
EP. 2: Standard Treatment Approaches in HER2+ MBC
Giuseppe Curigliano, MD, PhD
A global perspective regarding standards of care for treating HER2-positive metastatic breast cancer in earlier treatment settings.
EP. 4: Subgroup Analyses of DESTINY-Breast03 in HER2+ MBC
Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center
Subgroup analyses of the DESTINY-Breast03 study evaluating trastuzumab deruxtecan as second-line therapy in HER2-positive metastatic breast cancer.
EP. 5: Managing TRAEs Associated With Novel HER2+ MBC Therapies
Volkmar Mueller, MD, Prof Dr, University Medical Center Hamburg-Eppendorf
Recommendations for monitoring for and managing adverse events associated with newer therapies being sequenced into HER2+ metastatic breast cancer treatment algorithms.
EP. 6: T-DXd for HER2+ MBC and Interstitial Lung Disease
Carmen Criscitiello, MD, PhD
Recommendations for managing patients with HER2+ metastatic breast cancer who develop interstitial lung disease, an adverse event of trastuzumab deruxtecan.
EP. 8: Updates to HER2CLIMB in HER2+ MBC
Giuseppe Curigliano, MD, PhD
Breast oncologists react to updated overall survival data, progression-free survival data, and quality-of-life data from the HER2CLIMB study of tucatinib for HER2+ metastatic breast cancer, as well as consider using the drug in combination with other novel therapies.
EP. 9: Updates in the Management of HER2+ MBC With Brain Metastases
Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center
Recent advances in the characterization and treatment of patients with HER2-positive metastatic breast cancer and brain metastases.
EP. 10: ADCs Under Investigation for HER2+ MBC
Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center
Expectations as to where antibody-drug conjugates in the pipeline will fit into HER2-positive metastatic breast cancer treatment algorithms.
EP. 11: Therapeutic Sequencing in HER2+ MBC
Giuseppe Curigliano, MD, PhD
A global perspective pertaining to how to best sequence therapies used to treat HER2+ metastatic breast cancer based on treatment advances and data presented on at ESMO 2021.
EP. 12: Optimizing Therapy in HER2+ MBC Across the Globe
Giuseppe Curigliano, MD, PhD
A global perspective on managing patients with HER2-positive metastatic breast cancer through multiple lines of therapy based on treatment advances.
